This site is intended for healthcare professionals
A close up image of a microscope
  • Home
  • /
  • Clinical trials
  • /
  • Hand and foot dermatitis
  • /
  • Efficacy, Safety, and Tolerability of Abrocitinib ...
Clinical trial

Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Read time: 1 mins
Last updated:10th Jun 2024
Status: NOT YET RECRUITING
Identifier: NCT06283550
Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy


ClinicalTrials.gov ID: NCT06283550

Sponsor: Innovaderm Research Inc.
Information provided by: Innovaderm Research Inc. (Responsible Party)
Last Update Posted: 2024-02-29

Brief Summary:
This study aims to evaluate the safety, efficacy and tolerability of abrocitinib in subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

Detailed Description:
This randomized, double-blind, placebo-controlled, multicenter, phase 2 study aims to evaluate the efficacy of abrocitinib in 84 adult subjects with moderate to severe chronic hand eczema, and its effects on skin biomarkers using a noninvasive method of tape stripping.

Official Title:
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy

Intervention / Treatment: 
- Drug: Abrocitinib 200 mg
- Drug: Abrocitinib 100 mg
- Drug: Placebo

Category Value
Study Start (Estimated) 2024-04
Primary Completion (Estimated) 2025-05
Study Completion (Estimated) 2025-08
Enrollment (Estimated) 84
Study Type Interventional
Phase Phase 2
Other Study ID Numbers
INNO-6052


View full details